Login / Signup

Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.

Diane ItoChaoling FengChristine FuChong KimJames WuJosh EpsteinJulia Thornton SniderAdam S DuVall
Published in: Expert review of pharmacoeconomics & outcomes research (2023)
During the period ending in 2020, patients relapsed frequently, incurring high HRU and costs across LoTs. More effective treatments with long-lasting remissions in R/R MCL may reduce healthcare burden.
Keyphrases